Today Kedrion welcomed a delegation of institutional and political representatives, and donor and patient associations at its production hub in Bolognana, in the Province of Lucca, Italy.
The event highlighted the crucial role of plasma as a raw material for the production of lifesaving drugs for people with rare diseases. During the event, Kedrion representatives explained the complex process of transforming plasma, a unique and indispensable resource in the biopharmaceutical sector.
The event also served as an opportunity to reaffirm the company’s commitment to remaining true to its roots as an Italian company, while continuing to grow into a multinational corporation capable of competing in an increasingly globalized market.
“We were very pleased to welcome a large delegation of representatives from institutions and members of the patient and donor communities, with whom we had the opportunity to engage in dialogue and to present the new direction of the company,” said Paolo Marcucci, Chairman of Kedrion. “Today, Kedrion confirms its strong commitment to continue to support local communities and the territory where the company was founded and where it has its headquarters, which remains the reference point for the strategic choices of the entire Group at the global level.” “Our ongoing commitment to research and the development of new therapies,” he concluded, “guides us towards a future of hope and progress, and collaboration between all the actors in the system is essential to guarantee the necessary care to those who need it.”
“This day was an opportunity to reaffirm our goal of strengthening Kedrion’s industrial presence in Italy and, therefore, to continue investing in the country,” explained Ugo Di Francesco, CEO of Kedrion. “We aim to enhance the fractionation capacity of the Bolognana plant with the ultimate goal of expanding patient access to plasma-derived medicines worldwide. We want to make Bolognana an increasingly cutting-edge hub for research, development and production of plasma-derived medicines for the treatment of rare and ultra-rare diseases.”
Plasma processing represents a complex and crucial phase in the production of plasma-derived medicines. Unlike traditional drugs, plasma cannot be synthesized in the laboratory and requires a lengthy manufacturing process of 8 to 12 months.
This unique characteristic of the biopharmaceutical sector underlines the importance of plasma donation and the value of a company like Kedrion in transforming this gift into vital therapies for patients suffering from rare diseases.
With plasma as the connection between the generosity of donors and patient care, Kedrion confirms its role as a beacon of hope in the fight against rare diseases, by promoting an open and collaborative dialogue centered on people and communities.
Among the institutional guests who attended the event were: Italian Parliament members Elisa Montemagni, Riccardo Zucconi, Davide Faraone, Annarita Patriarca, the President of the Tuscany Region Eugenio Giani, regional councilor Leonardo Marras (Economy and Tourism), and regional councilors Enrico Sostegni, Gianni Anselmi, Marco Stella, Valentina Mercanti, Mario Puppa and Massimiliano Baldini. Also present were the President of the Province of Lucca, Marcello Pierucci, and the mayors of Barga, Gallicano and Castelnuovo di Garfagnana, Caterina Campani, Davide Saisi and Andrea Tagliasacchi.
The event also saw the involvement of Avis Nazionale, with the presence of the President, Gianpietro Briola, and of Fratres Nazionale; the President of the Italian Association of Primary Immunodeficiencies (AIP) Alessandro Segato, and EUPATI (Expert Patient Academy) representative Fabiana Ruggiero participated in the initiative, too.
